Press Releases

Date	Title	Company
10-Feb-2022	Socially Determined Expands Depth and Breadth of Healthcare Expertise in the C-Suite with Two New Executive Hires	Businesswire
10-Feb-2022	Galvanize Climate Solutions Announces Key Leadership Hires	Businesswire
10-Feb-2022	Pharma R&D Pipeline and New Product Launches Reach Record Levels in 2021 According to New IQVIA Institute for Human Data Science Report	Businesswire
10-Feb-2022	Biotechnology Services Global Market Report 2022 Featuring Novartis, Fisher BioService, Pfizer, Novo Nordisk, BioAlps, Precision for Medicine, Sartorius and Aldevron - ResearchAndMarkets.com	Businesswire
10-Feb-2022	Indapta Therapeutics Names Mark W. Frohlich, M.D., Chief Executive Officer and Raises Over $50 Million in Series A Financing and Commitments to Advance Development of G-NK Cell Therapy to Treat Multiple Types of Cancer	Businesswire
10-Feb-2022	Axcella Therapeutics to Participate in the SVB Leerink Global Healthcare Conference	Businesswire
10-Feb-2022	Global Artificial Intelligence in Healthcare Intellectual Property Landscape Report 2022 - ResearchAndMarkets.com	Businesswire
10-Feb-2022	Physical, Engineering, And Life Sciences Global Market Research Report 2022 - ResearchAndMarkets.com	Businesswire
10-Feb-2022	Labcorp Announces 2021 Fourth Quarter and Full-Year Results	Businesswire
10-Feb-2022	CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK	CureVac
10-Feb-2022	Enanta Pharmaceuticals to Present at the SVB Leerink 11th Annual Global Healthcare Conference	Businesswire
10-Feb-2022	MICA Biosystems to collaborate with the Cell and Gene Therapy Catapult	Cell and Gene Therapy Catapult (CGT Catapult),
10-Feb-2022	Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK’s MHRA Innovation Passport	Theragnostics
10-Feb-2022	Merck to Participate in the 11th Annual SVB Leerink Global Healthcare Conference	Businesswire
10-Feb-2022	Key Sessions during the Highly Potent Active Pharmaceutical Conference Released	SMi Group
10-Feb-2022	Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2021	Sosei Heptares
10-Feb-2022	Period of significant activity with $674 million raised by the portfolio and third successful exit to date – proposed sale of Gyroscope for up to $1.5 billion	Syncona Limited
10-Feb-2022	FDA accepts Dupixent® (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis	Sanofi
10-Feb-2022	Ixaka Expands Management Team with Multiple Appointments	Ixaka Ltd
10-Feb-2022	Olipudase alfa shown to provide sustained improvement across multiple clinical manifestations of ASMD	Sanofi